1. Home
  2. AEVA vs TLSI Comparison

AEVA vs TLSI Comparison

Compare AEVA & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aeva Technologies Inc.

AEVA

Aeva Technologies Inc.

HOLD

Current Price

$15.65

Market Cap

1.1B

ML Signal

HOLD

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

HOLD

Current Price

$4.43

Market Cap

270.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEVA
TLSI
Founded
2019
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
270.2M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
AEVA
TLSI
Price
$15.65
$4.43
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
★ $26.50
$7.00
AVG Volume (30 Days)
★ 1.3M
231.9K
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 10.53
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $45,151,000.00
Revenue This Year
$85.37
$35.45
Revenue Next Year
$132.72
$37.58
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 53.41
52 Week Low
$8.83
$2.20
52 Week High
$31.30
$7.95

Technical Indicators

Market Signals
Indicator
AEVA
TLSI
Relative Strength Index (RSI) 46.32 35.40
Support Level $13.77 $4.28
Resistance Level $16.67 $4.47
Average True Range (ATR) 0.83 0.36
MACD 0.25 -0.04
Stochastic Oscillator 63.84 2.32

Price Performance

Historical Comparison
AEVA
TLSI

About AEVA Aeva Technologies Inc.

Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The 4D LiDAR sensors are designed to detect both velocity and position, supporting perception and decision-making in automated systems. The company operates in North America, EMEA, and Asia. The company's revenue consists of sales of perception solutions or sensing systems and non-recurring engineering services. Geographically, it derives the majority of its revenue from North America.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Share on Social Networks: